Common Stock, Value, Issued of CITIUS ONCOLOGY, INC. from 31 Dec 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly Common Stock, Value, Issued in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Common Stock, Value, Issued for the quarter ending 31 Dec 2025 was $8,480, a 19% increase year-over-year.
- Source SEC data
- View on sec.gov
Common Stock, Value, Issued, Quarterly (USD)
Common Stock, Value, Issued, YoY Quarterly Change (%)
CITIUS ONCOLOGY, INC. Quarterly Common Stock, Value, Issued (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $8,480 | +$1,325 | +19% | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2025 | $8,351 | +$1,196 | +17% | 30 Sep 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q2 2025 | $7,155 | +$6,988 | +4184% | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 |
| Q1 2025 | $7,155 | +$6,988 | +4184% | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 |
| Q4 2024 | $7,155 | +$6,988 | +4184% | 31 Dec 2024 | 10-Q | 14 Feb 2025 | 2025 | Q1 |
| Q3 2024 | $7,155 | +$405 | +6% | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q2 2024 | $167 | -$75 | -31% | 30 Jun 2024 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q1 2024 | $167 | -$75 | -31% | 31 Mar 2024 | 10-Q | 20 May 2024 | 2024 | Q1 |
| Q4 2023 | $167 | -$75 | -31% | 31 Dec 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q3 2023 | $6,750 | +$6,577 | +3802% | 30 Sep 2023 | 10-K | 27 Dec 2024 | 2024 | FY |
| Q2 2023 | $242 | 30 Jun 2023 | 10-Q | 16 Aug 2023 | 2023 | Q2 | ||
| Q1 2023 | $242 | 31 Mar 2023 | 10-Q | 15 May 2023 | 2023 | Q1 | ||
| Q4 2022 | $242 | +$69 | +40% | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY |
| Q3 2022 | $173 | 30 Sep 2022 | 10-Q | 28 Nov 2022 | 2022 | Q3 | ||
| Q4 2021 | $173 | 31 Dec 2021 | 10-K | 17 Apr 2023 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.